Hemorai

We're Boston-bound!
Hemorai is honored to be a CAPCaT awardee pitching at the 7th Annual Point-of-Care Showcase, presented by the UMass Center for Advancing Point of Care Technologies (CAPCaT) and M2D2.
Our CEO, Hector Torres, will take the stage to share Hemorai's mission — Saving Lives Through Early Blood Loss Detection — with investors, strategic partners, and the wider digital health community.
📅 Tuesday, June 2, 2026 · 3:00–8:00 PM ET
📍 Mintz, 1 Financial Center, Boston, MA
Investors and strategic partners: the showcase is built for exactly this — connecting with emerging point-of-care innovators ahead of the curve. We'd welcome the chance to meet you there and share where HemoraI is headed.
🎟️ Register: https://www.eventbrite.com/e/capcat-7th-annual-point-of-care-showcase-tickets-1984333168925
Learn more at https://hemorai.com
UMass Chan Medical School

CAPCaT 7th Annual Point-of-Care Showcase Catch the pitches from innovative CAPCaT awardees. Plus, learn how to forge partnerships with investors and large companies.

The FDA spent years studying why pulse oximeters work differently on different skin tones. Last month, the results came back "confusing."

After testing 631 patients, researchers still can't agree on how to fix the problem. Meanwhile, the FDA's proposed new rules from 2025 remain stuck in draft form.

Here's the thing: you can't regulate your way out of a physics problem. Traditional pulse oximeters measure light absorption, and melanin absorbs light. That's not a bug to fix. It's a design limitation.

That's why at Hemorai, we use a completely different approach. Our technology measures how light bounces off moving blood cells, not how much gets absorbed. The result? Accurate readings regardless of skin tone.

When it comes to detecting life-threatening blood loss in new mothers (the #1 cause of maternal death worldwide), accuracy isn't optional. It's everything.